PresbyLASIK

From Wikipedia, the free encyclopedia
Jump to: navigation, search

PresbyLASIK is a surgical technique for presbyopic visual correction using Excimer LASER ablation.

PresbyLASIK treatment uses the principles of LASIK surgery to create a multifocal corneal surface aimed at reducing near vision spectacle dependence in presbyopic patients. Among the presbyLASIK techniques, the Excimer LASER ablation creates a central area which is hyperpositive for near vision leaving the midperipheral cornea for far vision.[1]

The first presbyopia treatment with excimer laser was done with the monovision technique LASIK. Some authors[who?] consider the PresbyLASIK the next step after monovision LASIK.

While an overall improvement in visual acuity has been recorded for both near and distance vision, safety and quality of vision have been compromised.[2] It has been reported that 20% of presbyLASIK-treated eyes lost two lines of best-corrected visual acuity at distance, and 52% of eyes lost two lines of best-corrected visual acuity for near vision, while only 48% of eyes achieved 20/20 uncorrected visual acuity.[2]

More recently, Supracor, a central presbylasik technique designed by Technolas, has been CE marked and approved for hyperopic presbyopes. Dr. Soler´s team, at Barcelona´s, have recently presented their one year results, at the 16th ESCRS winter meeting, and reported that more than 90% of patients had binocular distance and near vision of 0.8 or more, without glasses. Their results show symmetrical SUPRACOR (target -0.50 for both eyes) is safe, effective, and stable, in the short term. These patients will be followed-up as new protocols are being tested with asymmetrical Supracor ( emmetropia for dominant eye; -0.50 sphere for non dominant eye) aimed at younger presbyopic patients.

Surgical procedures for the correction of presbyopia, without reshaping the cornea, were proposed by Scharcker, M.D, using scleral band expansion (SBE), and J.T. Lin, Ph.D, using a laser scleral ablation in US Pat # 6,258,082 (2001). These procedures are different from the Presby-Lasik (monovision or bifocal) and are able to cause the true increase of accommodation of the eye. However, these procedures are still in their clinical trials pending FDA approval.

See also[edit]

References[edit]

  1. ^ Dolores Ortiz, PhD, Carlos Illueca, PhD, Jorge L. Alió, MD, PhD (1 January 2008). "PresbyLASIK versus multifocal refractive IOLs". Ophthalmology Times Europe 4 (1). Retrieved 2008-10-24. 
  2. ^ a b Alio JL, Chaubard JJ, Caliz A, Sala E, Patel S. Correction of presbyopia by technovision central multifocal LASIK (presbyLASIK). J Refract Surg. 2006;22:453-460

References 1. ^ Dolores Ortiz, PhD, Carlos Illueca, PhD, Jorge L. Alió, MD, PhD (1 January 2008). "PresbyLASIK versus multifocal refractive IOLs". Ophthalmology Times Europe 4 (1). http://www.oteurope.com/ophthalmologytimeseurope/Refractive/PresbyLASIK-versus-multifocal-refractive-IOLs/ArticleStandard/Article/detail/489731. Retrieved 2008-10-24. 2. Epstein Robert L and Gurgos Mark A, “ Presbyopia treatment by monocular peripheral presbyLASIK”, J Refract Surg. 2009 Jun;25(6):516-23